Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic and Mounjaro, the pharmaceutical company says.

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly continues to find ways to fend off the increasingly stiff competition in this market. Several companies are working on oral formulations of GLP-1 therapies. Others are looking into long ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

Telehealth partners for Eli Lilly continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the pharma giant to end copycat sales after the FDA ended a years-long shortage of ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

Eli Lilly continues to find ways to fend off the increasingly stiff competition in this market. Several companies are working on oral formulations of GLP-1 therapies. Others are looking into long ...